✨ Free AI Report
OKYO Pharma Limited: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research OKYO Pharma Limited
Company Research

OKYO Pharma Limited: Business Overview, Financials & Competitive Analysis

OKYO Pharma Limited scores 6/10 on the AskCyborg Cyborg Score (Solid). Clinical-stage eye disease specialist with near-term Phase 2b/3 catalysts and novel mechanism in large addressable markets, balanced against typical biotech development risks. OKYO demonstrates solid fundamentals as a clinical-stage company with a clear therapeutic focus, recent Phase II trial completions, and fresh capital funding. However, as a pre-revenue biotech.

What is OKYO Pharma Limited's industry? OKYO Pharma Limited (okyopharma.com) operates in Biopharmaceutical - Ophthalmology/Eye Diseases. AskCyborg classifies OKYO Pharma Limited under Biopharmaceutical - Ophthalmology/Eye Diseases in its company registry.

OKYO Pharma is a UK-based clinical-stage biopharmaceutical company focused on developing therapeutics for inflammatory eye diseases and ocular pain. The company's lead candidate, urcosimod, is advancing through Phase ...

6/ 10Solid

Cyborg Score thesis

Clinical-stage eye disease specialist with near-term Phase 2b/3 catalysts and novel mechanism in large addressable markets,...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Ophthalmology/Eye Diseases
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest OKYO Pharma Limited Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for OKYO Pharma Limited

AskCyborg analysts argue the bull and bear cases for OKYO Pharma Limited across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
OKYO Pharma Limited OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

OKYO Pharma Limited Overview

Pro stress-test →

OKYO Pharma is a UK-based clinical-stage biopharmaceutical company focused on developing therapeutics for inflammatory eye diseases and ocular pain. The company's lead candidate, urcosimod, is advancing through Phase II trials for dry eye disease and neuropathic corneal pain, addressing significant unmet medical needs affecting hundreds of millions of patients globally.

Strategic Profile

Pro stress-test →

OKYO leverages its expertise in G protein-coupled receptor (GPCR) biology with a pipeline targeting two large indications: neuropathic corneal pain (NCP), for which it received first FDA IND clearance, and dry eye disease. The company recently raised $20 million (February 2026) to fund Phase 2b/3 trials, demonstrating investor confidence in its clinical progress and commercial potential.

Competitive Landscape

Pro stress-test →

OKYO competes in the ophthalmology therapeutics space against larger pharma players developing dry eye and ocular pain treatments. Key competitive advantage stems from its novel GPCR target (chemerin receptor agonist) and first-mover FDA status in NCP. Direct competitors include Allergan/AbbVie (eye disease portfolio) and other clinical-stage biotech firms, though OKYO's specific mechanism differentiates its therapeutic approach.

Industry Context

OKYO Pharma Limited operates in Biopharmaceutical - Ophthalmology/Eye Diseases.

Key facts

Founded: 2007 · Headquarters: London, United Kingdom

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on OKYO Pharma Limited.

  • Urcosimod completed Phase 2 trials for neuropathic corneal pain; Phase 2b/3 initiation planned H1 2026 with ~150 patient cohort
  • OKYO holds first-mover FDA advantage—only company with IND clearance specifically for neuropathic corneal pain treatment
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026$20 million public share offering priced at $1.85/share to fund Phase 2b/3 trial expansion
  • January 2025Quarterly business updates on urcosimod development program advancement
  • +1 moreTrack every material event for OKYO Pharma Limited as it happens. Explore monitoring →
Get alerted when OKYO Pharma Limited has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Dry eye and ocular inflammation portfolioEstablished ophthalmology player with marketed dry eye therapies→Ocular pain and inflammation programsVarious development-stage competitors targeting similar indications→

Compare OKYO Pharma Limited with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

OKYO Pharma Limited operates in Biopharmaceutical - Ophthalmology/Eye Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Ophthalmology/Eye Diseases research →
NEW · MCP server

Ask your AI assistant about OKYO Pharma Limited

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare OKYO Pharma Limited and its top competitor on Cyborg Score”
“What did OKYO Pharma Limited do this quarter?”
“Is OKYO Pharma Limited a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does OKYO Pharma Limited do?+
OKYO Pharma is a UK-based clinical-stage biopharmaceutical company focused on developing therapeutics for inflammatory eye diseases and ocular pain. The company's lead candidate, urcosimod, is advancing through Phase ...
What is OKYO Pharma Limited's Cyborg Score?+
OKYO Pharma Limited has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are OKYO Pharma Limited's main competitors?+
Named competitors include Dry eye and ocular inflammation portfolio, Ocular pain and inflammation programs. The full competitive landscape is in the AskCyborg report.
How can I get the full OKYO Pharma Limited research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the OKYO Pharma Limited research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track OKYO Pharma Limited over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.